Press Releases

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

2014
Dec 2014 | Download as pdf

St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

Dec 2014 | Download as pdf

4 cheap small cap stocks Iíve got my eye for Christmas more

Dec 2014 | Download as pdf

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Dec 2014 | Download as pdf

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

Dec 2014 | Download as pdf

RBA to cut rates in 2015: Still want to invest in term deposits? more

Nov 2014 | Download as pdf

Can robots help stop the Ebola outbreak? more

Nov 2014 | Download as pdf

Robots Help Fight Ebola more

Nov 2014 | Download as pdf

South Florida Hospital Unveils Ebola-Zapping Robot more

Nov 2014 | Download as pdf

Sonoma Valley Hospital uses robot to kill germs more

Nov 2014 | Download as pdf

Robots go to war against Ebola more

Nov 2014 | Download as pdf

New iTraumaCare CEO to pursue big growth more

Nov 2014 | Download as pdf

UAB and SRI have plans to spinoff more success more

Nov 2014 | Download as pdf

Launch of Galderma's new acne products more

Nov 2014 | Download as pdf

iTraumaCare’s new CEO to help company secure new funding more

Oct 2014 | Download as pdf

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Oct 2014 | Download as pdf

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Oct 2014 | Download as pdf

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Oct 2014 | Download as pdf

Robot fights germs at Sharp Chula Vista Medical Center more

Oct 2014 | Download as pdf

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

Oct 2014 | Download as pdf

How do we get rid of the endotoxins? Birmingham's  has the solution more

Oct 2014 | Download as pdf

Medical Device ® Positions New Leader for Next-Level Growth more

Oct 2014 |

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Oct 2014 | Download as pdf

Germ-zapping robot Gigi sets its sights on Ebola more

Oct 2014 | Download as pdf

Morningside Ventures leads a Series B round for DNAtrix more

Oct 2014 | Download as pdf

StemBioSys secures new research space at BioBridge Global more

Oct 2014 | Download as pdf

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Oct 2014 | Download as pdf

Company invents germ-zapping robot more

Sept 2014 | Download as pdf

Xenex Congratulates Houston Cancer Hospital more

Sept 2014 | Download as pdf

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

Sept 2014 | Download as pdf

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Sept 2014 | Download as pdf

Targeted Technology raises more than $40 million more

Sept 2014 | Download as pdf

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Sept 2014 | Download as pdf

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Aug 2014 | Download as pdf

Three Birmingham companies recognized in PwC report more

Aug 2014 | Download as pdf

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

Aug 2014 | Download as pdf

International dermatology company Galderma confirmed more

Aug 2014 | Download as pdf

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

Aug 2014 | Download as pdf

San Antonio luring biotech firms with venture capital more

July 2014 | Download as pdf

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

July 2014 | Download as pdf

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

July 2014 | Download as pdf

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

July 2014 | Download as pdf

Milford hospital enlists robots in war against infections more

July 2014 | Download as pdf

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

July 2014 | Download as pdf

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

July 2014 | Download as pdf

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

July 2014 | Download as pdf

TFS flags record full-year profit more

June 2014 | Download as pdf

Sweet scented sandalwood flavour of month more

June 2014 | Download as pdf

House committee looks for new technology in Veterans Affairs hospitals more

June 2014 | Download as pdf

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

May 2014 | Download as pdf

CEO shakeup at San Antonio biotech company StemBioSys more

May 2014 | Download as pdf

First harvest to be completed in June more

Mar 2014 | Download as pdf

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

Mar 2014 | Download as pdf

San Antonio biotech firm readies skin treatment for distribution more

Mar 2014 | Download as pdf

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Mar 2014 | Download as pdf

Medical technologies conference announces speaker lineup more

Mar 2014 | Download as pdf

Australian sandalwood sells for millions more

Mar 2014 | Download as pdf

Sandalwood exports as good as gold more

Feb 2014 | Download as pdf

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

Feb 2014 | Download as pdf

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

Feb 2014 | Download as pdf

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas

Grant to Be Used to Fund Ongoing Clinical Trials for Brain Cancer

HOUSTON--(BUSINESS WIRE)--DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that it has been awarded a product development grant for $10.8 million to fund the company’s clinical-stage program in glioblastoma—the most aggressive type of brain cancer. The grant from the Cancer Prevention and Research Institute of Texas (CPRIT) is entitled “Clinical development and commercialization of oncolytic adenovirus for treating malignant glioma.”

“We appreciate the support from such a reputable organization as CPRIT, as it offers additional validation of our cancer program and the clinical benefits that we continue to observe in our clinical trials including long-term survival and tumor destruction.”

The grant awarded to DNAtrix will be used to drive the clinical development of DNX-2401, the lead product candidate that is currently undergoing a Phase Ib trial in combination with temozolomide for recurrent glioblastoma. DNX-2401 uses a genetically modified adenovirus that kills tumor cells selectively. In an earlier Phase I study in recurrent glioblastoma, DNX-2401 demonstrated an excellent safety profile and promising efficacy results.

The CPRIT grants support oncology-focused research and development conducted by Texas-based companies and relocation of existing oncology-focused companies to Texas. These grants cover a range of product development sectors including therapeutics, devices and drug development. After undergoing CPRIT’s review process, the grants were recommended by their respective program review councils and approved by the Oversight Committee.

“We are thrilled to receive this generous grant from the Cancer Prevention and Research Institute of Texas, as these funds will accelerate DNAtrix’s efforts to pursue the clinical development of our lead oncolytic virus product for glioblastoma,” said Dr. Frank Tufaro, Chief Executive Officer of DNAtrix. “We appreciate the support from such a reputable organization as CPRIT, as it offers additional validation of our cancer program and the clinical benefits that we continue to observe in our clinical trials including long-term survival and tumor destruction.”

About CPRIT
Beginning operations in 2009, CPRIT provides funding for scientific research, product development and prevention programs. Learn more at www.cprit.state.tx.us.

About DNAtrix Inc.
As a clinical-stage company developing modified oncolytic viruses for the treatment of the most aggressive forms of cancer, DNAtrix is a privately held company headquartered in Houston, Texas. For more information, please visit the company website at http://www.dnatrix.com.

Contacts
DNAtrix Inc.
Michelle Chen, 650-690-6470
Chief Business Officer
mchen@dnatrix.com back

Feb 2014 | Download as pdf

ViroXis Corporation Achieves Key Clinical Milestones more

Jan 2014 | Download as pdf

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more